Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Psychopharmacology (Berl). 2014 Apr 30;231(21):4231–4240. doi: 10.1007/s00213-014-3566-6

Table 3.

[11C]NNC112 BPF by Diagnostic Group for PFCa and Striatal ROIs

ROI Controls (n=20b) SPD (n=18) pc
PFC:
 DLPFC 357.61 ± 109.66 408.58 ± 187.08 0.306
 MPFC 373.28 ± 129.22 414.40 ± 179.27d 0.466
 OFC 377.23 ± 160.76 447.50 ± 207.56 0.248

Striatal:
 VST 663.41 ± 219.96 877.40 ± 335.61 0.025
 preDCA 762.28 ± 237.42 928.88 ± 359.64 0.097
 preDPU 813.18 ± 266.70 990.80 ± 380.12 0.101
 postCA 584.59 ± 196.56 698.07 ± 309.58 0.181
 postPU 781.91 ± 265.39 939.80 ± 363.83 0.132
 whole STR 755.49 ± 241.89 927.82 ± 358.57 0.088

Note. Mean ± Standard Deviation (observed).

STR=striatum; see Table 2 for other abbreviations.

a

BPF values for all PFC (but not striatal) ROIs were adjusted to correct for partial volume effects (PVE); see text.

b

n=20: BPF values were missing for one control due to unavailability of fp term.

c

Group comparisons of the estimated marginal means derived from linear mixed modeling (see text) with the exception of the composite whole STR; for this region, an independent-samples t-test was used.

d

n=17: One SPD participant’s values were excluded due to excessive noise in the VT measurement.

HHS Vulnerability Disclosure